GILEAD SCIENCES, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
GILEAD SCIENCES, INC. (GILD) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $12.15 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-06
- GILEAD SCIENCES, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-30 was $12.04B, a 19642.62% increase year-over-year.
- GILEAD SCIENCES, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-03-31 was $107.00M, a 57.71% decline year-over-year.
- GILEAD SCIENCES, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $539.00M.
- GILEAD SCIENCES, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $170.00M, a 66.34% decline year-over-year.
- GILEAD SCIENCES, INC. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $1.02B, a 78.04% decline from fiscal 2024.
- GILEAD SCIENCES, INC. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $4.66B, a 303.72% increase from fiscal 2023.
- GILEAD SCIENCES, INC. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $1.16B, a 22.35% increase from fiscal 2022.
- GILEAD SCIENCES, INC. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $944.00M, a 0.53% increase from fiscal 2021.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.04B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $12.15B 10-Q · filed 2026-08-06 | $12.69B derived: sum of 3 quarters · filed 2026-08-06 | $12.86B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $107.00M 10-Q · filed 2026-05-07 | $646.00M derived: sum of 2 quarters · filed 2026-05-07 | $816.00M derived: sum of 3 quarters · filed 2026-05-07 | $877.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $539.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $709.00M derived: sum of 2 quarters · filed 2026-02-24 | $770.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.02B 10-K · filed 2026-02-24 |
| 2025-09-30 | $170.00M 10-Q · filed 2025-11-07 | $231.00M derived: sum of 2 quarters · filed 2025-11-07 | $485.00M 10-Q · filed 2025-11-07 | $473.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | $61.00M 10-Q · filed 2025-08-07 | $315.00M 10-Q · filed 2026-08-06 | $303.00M derived: sum of 3 quarters · filed 2026-05-07 | $808.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | $253.00M 10-Q · filed 2026-05-07 | $242.00M derived: sum of 2 quarters · filed 2026-05-07 | $747.00M derived: sum of 3 quarters · filed 2026-05-07 | $785.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $494.00M derived: sum of 2 quarters · filed 2026-02-24 | $532.00M derived: sum of 3 quarters · filed 2026-02-24 | $4.66B 10-K · filed 2026-02-24 |
| 2024-09-30 | $505.00M 10-Q · filed 2025-11-07 | $543.00M derived: sum of 2 quarters · filed 2025-11-07 | $4.67B 10-Q · filed 2025-11-07 | $5.02B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $38.00M 10-Q · filed 2025-08-07 | $4.17B 10-Q · filed 2025-08-07 | $4.52B derived: sum of 3 quarters · filed 2026-02-24 | $4.61B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $4.13B 10-Q · filed 2025-05-07 | $4.48B derived: sum of 2 quarters · filed 2026-02-24 | $4.57B derived: sum of 3 quarters · filed 2026-02-24 | $4.80B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $347.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $438.00M derived: sum of 2 quarters · filed 2026-02-24 | $674.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.16B 10-K · filed 2026-02-24 |
| 2023-09-30 | $91.00M 10-Q · filed 2024-11-12 | $327.00M derived: sum of 2 quarters · filed 2024-11-12 | $808.00M 10-Q · filed 2024-11-12 | $966.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $236.00M 10-Q · filed 2024-08-08 | $717.00M 10-Q · filed 2024-08-08 | $875.00M derived: sum of 3 quarters · filed 2025-02-28 | $1.32B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $481.00M 10-Q · filed 2024-05-08 | $639.00M derived: sum of 2 quarters · filed 2025-02-28 | $1.09B derived: sum of 3 quarters · filed 2025-02-28 | $1.42B derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $158.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $606.00M derived: sum of 2 quarters · filed 2025-02-28 | $936.00M derived: sum of 3 quarters · filed 2025-02-28 | $944.00M 10-K · filed 2025-02-28 |
| 2022-09-30 | $448.00M 10-Q · filed 2023-11-07 | $778.00M derived: sum of 2 quarters · filed 2023-11-07 | $786.00M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $330.00M 10-Q · filed 2023-08-04 | $338.00M 10-Q · filed 2023-08-04 | ||
| 2021-12-31 | $939.00M 10-K · filed 2024-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |